(AOF) – OSE Immunotherapeutics has announced the appointment of Alexandre Lebeaut by cooptation as independent director of the Company. A doctor of medicine, Alexandre Lebeaut has more than 25 years of experience and leadership in innovation, research and development, ranging from preclinical to the market, with great success, particularly in the fields of immunology, oncology, immuno-inflammation and infectious diseases. He has held various international positions, mainly in the United States.
More recently, Alexandre Lebeaut was “Executive Vice-President R&D and Chief Scientific Officer” at Ipsen in the United States. He currently leads an American non-profit organization, I-ACT for Children (Institute for Advanced Clinical Trials for Children), based in Maryland and dedicated to the development of pediatric drugs.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.